Walleye Capital’s LENZ Therapeutics LENZ Stock Holding History

Walleye Capital’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,604	Closed	-$57K	–	2763
2022 Q1	$57K	Buy	+1,604	New	+$100K	﹤0.01%	1830

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Walleye Capital's LENZ Position: Q2 2022 in Review

Walleye Capital sold out of LENZ Therapeutics (LENZ) in Q2 2022, closing a stake of 1,604 shares — an estimated $57K sold.

Walleye Capital first reported a position in LENZ in Q1 2022 and held it in 1 quarter. The position peaked at $57K in Q1 2022. 63 funds tracked by Wall St. Rank hold LENZ as of Q2 2022.

Walleye Capital reported no remaining LENZ Therapeutics position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 1,604 LENZ Therapeutics shares in Q2 2022, an estimated $57K.
Walleye Capital first reported a position in LENZ Therapeutics in Q1 2022 and held it in 1 quarter.
Walleye Capital's LENZ Therapeutics position peaked at $57K in Q1 2022.
63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.